Art. -Nr.: HY-13650

Indisulam

Name: Indisulam
Brand: MedChemExpress
SKU: HY-13650
Price: 36.00 USD
Availability: InStock
Rating: 5 (16 reviews)

(Synonyms: E 7070)

16 Cited Publications

Kundenbewertung

Based on 16 publication(s) in Google Scholar

Indisulam (E 7070) is a carbonic anhydrase inhibitor and RBM39 molecular glue degrader, with K_i values of 31, 15, and 24 nM against human carbonic anhydrase I, II, and IX, respectively, and a K_i value of 65 nM against bovine carbonic anhydrase IV. Indisulam promotes the recruitment of RBM39 to the CUL4-DCAF15 E3 ubiquitin ligase complex, triggering polyubiquitination and proteasomal degradation of RBM39. Indisulam induces aberrant pre-mRNA splicing, G1 cell cycle arrest, and cell death in cancer cells. As an anticancer agent, Indisulam drives tumor regression and growth inhibition in xenograft models. Indisulam can be used in research related to solid tumors, hematologic and lymphoid malignancies, colorectal cancer, and non-small cell lung cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.80%
CAS. Nr.: 165668-41-7
Formel: C₁₄H₁₂ClN₃O₄S₂
Molecular Weight:385.85

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 1 year , -20°C, 6 months

Indisulam Chemical Structure

CAS. Nr.: 165668-41-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (16)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]^[2]

hCA I

31 nM (Ki)

hCA II

15 nM (Ki)

hCA IX

24 nM (Ki)

bovine CA IV

65 nM (Ki)

RBM39

Alle Carbonic Anhydrase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC50	0.56 μM	Reduction of cell viability against human HCT-116 colorectal carcinoma cells incubated for 3 days measured by CellTiter-Glo Luminescent Cell Viability Assay. Reduction of cell viability against human HCT-116 colorectal carcinoma cells incubated for 3 days measured by CellTiter-Glo Luminescent Cell Viability Assay.	28302793
NCI-H1155	IC50	0.36 μM	Reduction of RBM39 protein levels (measured as luciferase activity of RBM39-Nluc) and cell viability against human H1155 non-small cell lung cancer cells incubated for 2 days. Reduction of RBM39 protein levels (measured as luciferase activity of RBM39-Nluc) and cell viability against human H1155 non-small cell lung cancer cells incubated for 2 days.	28302793
HCT-116	IC50	0.11 μg/mL	Antiproliferative activity against human HCT116 colorectal cancer cells assessed by MTT assay after 3 days of continuous incubation. Antiproliferative activity against human HCT116 colorectal cancer cells assessed by MTT assay after 3 days of continuous incubation.	11677118
NCI-H596	IC50	94 μg/mL	Antiproliferative activity against human NCI-H596 non-small cell lung cancer cells assessed by MTT assay after 3 days of continuous incubation. Antiproliferative activity against human NCI-H596 non-small cell lung cancer cells assessed by MTT assay after 3 days of continuous incubation.	11677118

In Vitro

Indisulam (administered for 3 days) potently reduces the viability of HCT-116 cells, with an IC₅₀ of 0.56 μM^[2].
Indisulam (treatment for 2 days) reduces the RBM39 protein level and cell viability of H1155 cells, with an IC₅₀ of 0.36 μM^[2].
Indisulam (3 days) exhibits a unique antiproliferative profile across 42 human tumor cell lines, with an IC₅₀ range from 0.11 μg/mL (HCT116 colorectal cancer) to 94 μg/mL (NCI-H596 non-small cell lung cancer)^[3].
Indisulam (0.015-33 μg/mL; 1-6 days) exerts time-dependent cytotoxicity against human colorectal cancer cell line HCT116. On day 6, doses of 0.14 μg/mL and above significantly reduce cell numbers, and a plateau is reached at doses of 1.2 μg/mL and higher^[3].
Indisulam (2 h) induces post-translational, dose-dependent degradation of RBM39 protein in HCT-116 cells, which relies on proteasome activity and requires ubiquitin-like modification of Cullin ring ligases^[2].
Indisulam (10 μM; 2 h) induces recruitment of wild-type RBM39 (but not the RBM39^G268V mutant) to the CUL4-DCAF15 E3 ubiquitin ligase complex in human colorectal cancer cells HCT-116^[2].
Indisulam (2 μM; 6-12 h) induces widespread exon skipping and intron retention in parental HCT-116 cells, and this effect depends on the degradation of RBM39-only minimal splicing defects are present in RBM39^G268V mutant cells^[2].
Indisulam (0.14-100 μg/mL; 12-48 h) induces time- and dose-dependent G1 phase cell cycle arrest in P388 mouse leukemia cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[3]

Cell Line:

P388 murine leukaemia cells
Concentration:

0.14, 0.41, 1.2, 3.7, 11, 33, 100 μg/mL
Incubation Time:

12 h; 24 h; 48 h
Result:

Accumulated P388 cells in the G1 phase at 33 μg/mL and higher after 12 h.
Increased G1 accumulation at 0.41-3.7 μg/mL after 24 h, and at 0.14-1.2 μg/mL after 48 h.
Detected dead cells and a sub-G1 population at 11 μg/mL and higher after 24 h, and at 3.7 μg/mL and higher after 48 h.

Cell Cytotoxicity Assay^[3]

Cell Line:

HCT116 human colorectal cancer cells
Concentration:

0.015, 0.045, 0.14, 0.41, 1.2, 3.7, 11, 33 μg/mL
Incubation Time:

1 day; 2 days; 3 days; 6 days
Result:

Showed no significant decrease in cell number on day 1 at any tested dose.
Induced cytotoxicity at 1.2-33 μg/mL in a time-dependent manner after day 1, with a plateau effect at 1.2 μg/mL.
Reduced cell number at 0.41 μg/mL after day 2 and at 0.14 μg/mL on day 6.
Caused no effect on cell proliferation at doses of 0.045 μg/mL and lower over 6 days.
Confirmed apoptotic cell death via DNA fragmentation after 2 days of exposure to 1.0 μg/mL.

In Vivo

Indisulam (25 mg/kg; intravenous injection; daily administration; for 8 consecutive days) induces complete tumor regression in nude mice bearing human HCT116 colon cancer or LX-1 lung cancer xenografts^[1].
Indisulam (25 mg/kg; intravenous injection; daily administration for 8 consecutive days) induces complete regression of parental HCT-116 colorectal cancer xenografts in Nod-Scid IL-2Rγ KO mice^[2].
Indisulam (6.25-200 mg/kg; intravenous injection; once daily for 4 consecutive days; single administration; once daily for 8 consecutive days; once every 4 days for a total of 4 times) induces dose- and regimen-dependent tumor growth inhibition and regression in HCT116 colorectal cancer xenografts. Among these regimens, the administration of 25 mg/kg/day for 8 consecutive days yields the optimal efficacy, resulting in a T/C value of 1% and a reduction of tumor volume to 1% of the initial volume^[3].
Indisulam (6.25-200 mg/kg; intravenous injection; once daily for 4 consecutive days; single administration; once daily for 8 consecutive days; once every 4 days for a total of 4 administrations) induces dose- and regimen-dependent tumor growth inhibition and regression in LX-1 lung cancer xenografts. Specifically, the regimen of 25 mg/kg/day administered once daily for 8 consecutive days maintains 80% of mice tumor-free for 5 months^[3].
Indisulam (12.5-100 mg/kg; intravenous injection; once daily for 4 consecutive days) induces tumor growth inhibition and regression of SW620 colorectal cancer xenografts, with a final T/C value of 34% and an RTVmin of 0.63^[3].
Indisulam (25-50 mg/kg; intravenous injection; once daily for 4 consecutive days) induces tumor growth inhibition and regression in HCT15 colorectal cancer xenografts, with a final T/C value of 26% and an RTVmin of 0.46^[3].
Indisulam (12.5-100 mg/kg; intravenous injection; once daily for 4 consecutive days) induces tumor growth inhibition in the PC-9 lung cancer xenograft model, resulting in a T/C value of 35% and an RTVmin of 0.93^[3].
Indisulam (25-50 mg/kg; intravenous injection; once daily for 4 consecutive days) induces tumor growth inhibition in the DLD-1 colorectal cancer xenograft model, with a T/C value of 54%^[3].
Indisulam (12.5-100 mg/kg; intravenous injection; once daily for 4 consecutive days) induces mild tumor growth inhibition in the WiDr colorectal cancer xenograft model, with a T/C value of 72%^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

nude^[1]
Dosage:

25 mg/kg
Administration:

i.v.; daily; 8 days
Result:

Caused complete tumor regression in human colon carcinoma HCT116 xenografts.
Caused complete tumor regression in human lung carcinoma LX-1 xenografts.

Animal Model:

Nod-Scid IL-2Rγ KO mice^[2]
Dosage:

25 mg/kg
Administration:

i.v.; daily; 8 days
Result:

Induced complete regression of tumors derived from parental HCT-116 cells.\nFailed to inhibit tumor growth, with treated tumors growing at a rate indistinguishable from vehicle-treated controls.

Animal Model:

BALB/c nu/nu (female, 7 weeks old, subcutaneous implantation of LX-1 human lung cancer tumour fragments)^[3]
Dosage:

100, 200 mg/kg (single dose); 25, 50 mg/kg (daily for 4 days); 6.25, 12.5, 25, 50 mg/kg (daily for 8 days); 50, 100, 200 mg/kg (every 4 days for 4 doses)
Administration:

i.v.; daily for 4 days; single dose; daily for 8 days; every 4 days for 4 doses
Result:

Achieved T/C of 80% at 12.5 mg/kg/day daily for 4 days.
Achieved RTVmin of 0.79 and T/C of 29% at 25 mg/kg/day daily for 4 days.
Achieved RTVmin of 0.27 and T/C of 11% at 50 mg/kg/day daily for 4 days.
Achieved RTVmin of 0.64 and T/C of 46% at 200 mg/kg single dose.
Achieved RTVmin of 0.79 and T/C of 30% at 25 mg/kg/day daily for 4 days (repeat cohort).
Achieved RTVmin of 0.27 and T/C of 12% at 50 mg/kg/day daily for 4 days (repeat cohort).
Achieved T/C of 43% at 6.25 mg/kg/day daily for 8 days.
Achieved RTVmin of 0.15 and T/C of 5% at 12.5 mg/kg/day daily for 8 days.
Achieved RTVmin of 0.03 and T/C of 0%, with 8/10 mice remaining tumour-free for 5 months at 25 mg/kg/day daily for 8 days.
Achieved RTVmin of 0.18 and T/C of 3% at 50 mg/kg/day every 4 days for 4 doses.
Achieved RTVmin of 0.02 and T/C of 0%, with 4/5 mice remaining tumour-free for 5 months at 100 mg/kg/day every 4 days for 4 doses.

Animal Model:

BALB/c nu/nu (female, 7 weeks old, subcutaneous implantation of SW620 human colon cancer cells)^[3]
Dosage:

12.5, 25, 50 mg/kg
Administration:

i.v.; daily for 4 days
Result:

Achieved T/C of 88% at 12.5 mg/kg/day daily for 4 days.
Achieved T/C of 67% at 25 mg/kg/day daily for 4 days.
Achieved RTVmin of 0.63 and T/C of 34% at 50 mg/kg/day daily for 4 days.
Caused all mice to die at 100 mg/kg/day daily for 4 days.

Animal Model:

BALB/c nu/nu (female, 7 weeks old, subcutaneous implantation of HCT15 human colon cancer cells)^[3]
Dosage:

25, 50 mg/kg
Administration:

i.v.; daily for 4 days
Result:

Achieved T/C of 74% at 25 mg/kg/day daily for 4 days.
Achieved RTVmin of 0.46 and T/C of 26% at 50 mg/kg/day daily for 4 days.

Animal Model:

BALB/c nu/nu (female, 7 weeks old, subcutaneous implantation of PC-9 human lung cancer cells)^[3]
Dosage:

12.5, 25, 50, 100 mg/kg
Administration:

i.v.; daily for 4 days
Result:

Achieved T/C of 89% at 12.5 mg/kg/day daily for 4 days.
Achieved T/C of 83% at 25 mg/kg/day daily for 4 days.
Achieved RTVmin of 0.93 and T/C of 35% at 50 mg/kg/day daily for 4 days.
Caused all mice to die at 100 mg/kg/day daily for 4 days.

Animal Model:

BALB/c nu/nu (female, 7 weeks old, subcutaneous implantation of DLD-1 human colon cancer cells)^[3]
Dosage:

25, 50 mg/kg
Administration:

i.v.; daily for 4 days
Result:

Achieved T/C of 83% at 25 mg/kg/day daily for 4 days.
Achieved T/C of 54% at 50 mg/kg/day daily for 4 days.

Animal Model:

BALB/c nu/nu (female, 7 weeks old, subcutaneous implantation of WiDr human colon cancer cells)^[3]
Dosage:

12.5, 25, 50, 100 mg/kg
Administration:

i.v.; daily for 4 days
Result:

Achieved T/C of 85% at 12.5 mg/kg/day daily for 4 days.
Achieved T/C of 77% at 25 mg/kg/day daily for 4 days.
Achieved T/C of 72% at 50 mg/kg/day daily for 4 days.
Caused all mice to die at 100 mg/kg/day daily for 4 days.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 165668-41-7
Appearance Solid
Molecular Weight 385.85
Formel C₁₄H₁₂ClN₃O₄S₂
Color White to pink
SMILES

O=S(C1=CC=C(S(=O)(N)=O)C=C1)(NC2=CC=CC3=C2NC=C3Cl)=O
Synonyms

E 7070
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (16)

All Cell Imaging/StainingApoptosis AnalysisWBIn Vivo Efficacy StudyIHC

Sort by:

Journal Impact Factor

Nat Chem Biol

Activity-based profiling of cullin-RING E3 networks by conformation-specific probes. [Abstract]

2023 Dec;19(12):1513-1523. PMID: 37653169
J Exp Clin Cancer Res

Targeting RBM39 through indisulam induced mis-splicing of mRNA to exert anti-cancer effects in T-cell acute lymphoblastic leukemia. [Abstract]

2024 Jul 24;43(1):205. PMID: 39044280

Indisulam purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2024 Jul 24;43(1):205. [Abstract]

Fluorescence microscopy images of the T-ALL cell lines J.gamma1 and Jurkat after 48 h of treatment with 1 μM and 5 μM Indisulam, respectively.

Indisulam purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2024 Jul 24;43(1):205. [Abstract]

Flow cytometry analysis was performed to assess apoptosis in T-ALL cells after 24 h of treatment with DMSO or various concentrations of Indisulam (1 μM and 5 μM) utilizing Annexin V and PI staining. The percentage of apoptotic cells was subjected to statistical evaluation.

Indisulam purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2024 Jul 24;43(1):205. [Abstract]

Western blot analysis was performed to validate the protein expression changes occurring in the J.gamma1 and Jurkat cell lines after treatment with Indisulam (1 μM and 5 μM) for 24 and 48 h, respectively.

Indisulam purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2024 Jul 24;43(1):205. [Abstract]

Compared with the control group, the Indisulam (12.5 mg/kg, i.p.)-treated group displayed a significant decrease in fluorescence intensity at four distinct time points posttreatment, demonstrating a substantial suppression of J.gamma1 cell proliferation in vivo.

Indisulam purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2024 Jul 24;43(1):205. [Abstract]

Immunohistochemical analyses of the Indisulam (12.5 mg/kg, i.p.)-treated group the mouse bone, liver, and spleen tissues revealed a decreased expression of Ki67 and RBM39.
J Exp Clin Cancer Res

MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma. [Abstract]

2023 Aug 21;42(1):214. PMID: 37599362
Oncogene

RBM39 promotes hepatocarcinogenesis by regulating RFX1's alternative splicing and subsequent activation of integrin signaling pathway. [Abstract]

2025 Jun;44(20):1488-1503. PMID: 40033026
Cell Mol Gastroenterol Hepatol

RBM39 Enhances Cholangiocarcinoma Growth Through EZH2-mediated WNT7B/β-catenin Pathway. [Abstract]

2025;19(1):101404. PMID: 39278404
Cell Rep

Transient splicing inhibition causes persistent DNA damage and chemotherapy vulnerability in triple-negative breast cancer. [Abstract]

2024 Sep 13;43(9):114751. PMID: 39276346
Cell Prolif

RBM39 Promotes Base Excision Repair to Facilitate the Progression of HCC by Stabilising OGG1 mRNA. [Abstract]

2025 Oct;58(10):e70059. PMID: 40364450
Cell Biosci

The RBM39 degrader indisulam inhibits acute megakaryoblastic leukemia by altering the alternative splicing of ZMYND8. [Abstract]

2025 Apr 13;15(1):46. PMID: 40223119
Biochim Biophys Acta Mol Cell Res

Regulatory role of RBM39 in acute myeloid leukemia: Mediation through the PI3K/AKT pathway. [Abstract]

2024 Jan;1871(1):119607. PMID: 37852323
Bioorg Med Chem

The splicing modulator sulfonamide indisulam reduces AR-V7 in prostate cancer cells. [Abstract]

2020 Oct 15;28(20):115712. PMID: 33069070
PLoS One

Indisulam synergizes with melphalan to inhibit Multiple Myeloma malignancy via targeting TOP2A. [Abstract]

2024 Apr 9;19(4):e0299019. PMID: 38593113
Res Sq

2026 Jun 2:rs.3.rs-9675139. PMID: 42282014
bioRxiv

Slice-PASEF: Maximising Ion Utilisation in LC-MS Proteomics. [Abstract]

2025 Sep 2:2022.10.31.514544. PMID: 40950106
bioRxiv

2024 Jul 25.
SSRN

2024 Jun 19.
University of Munich

2022 Oct.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (259.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5917 mL

12.9584 mL

25.9168 mL

5 mM

0.5183 mL

2.5917 mL

5.1834 mL

10 mM

0.2592 mL

1.2958 mL

2.5917 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.17 mg/mL (5.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.17 mg/mL (5.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.17 mg/mL (5.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (307 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Abbate F, et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorganic & medicinal chemistry letters. 2004 Jan 05;14(1):217-23. [Content Brief]

[2]. Han T, et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science (New York, N.Y.). 2017 Apr 28;356(6336):eaal3755. [Content Brief]

[3]. Ozawa Y, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. European journal of cancer (Oxford, England : 1990). 2001 Nov;37(17):2275-82. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5917 mL	12.9584 mL	25.9168 mL	64.7920 mL
	5 mM	0.5183 mL	2.5917 mL	5.1834 mL	12.9584 mL
	10 mM	0.2592 mL	1.2958 mL	2.5917 mL	6.4792 mL
	15 mM	0.1728 mL	0.8639 mL	1.7278 mL	4.3195 mL
	20 mM	0.1296 mL	0.6479 mL	1.2958 mL	3.2396 mL
	25 mM	0.1037 mL	0.5183 mL	1.0367 mL	2.5917 mL
	30 mM	0.0864 mL	0.4319 mL	0.8639 mL	2.1597 mL
	40 mM	0.0648 mL	0.3240 mL	0.6479 mL	1.6198 mL
	50 mM	0.0518 mL	0.2592 mL	0.5183 mL	1.2958 mL
	60 mM	0.0432 mL	0.2160 mL	0.4319 mL	1.0799 mL
	80 mM	0.0324 mL	0.1620 mL	0.3240 mL	0.8099 mL
	100 mM	0.0259 mL	0.1296 mL	0.2592 mL	0.6479 mL

Bioz

Indisulam

16 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Indisulam

Publications Citing Use of MedChemExpress (MCE) Indisulam

Alle Carbonic Anhydrase Isoform-spezifische Produkte anzeigen